Suppr超能文献

肝 X 受体配体的结构选择性机制: 和 研究。

Structurally Selective Mechanism of Liver X Receptor Ligand: and Studies.

机构信息

Research Center for Drug Discovery, School of Pharmaceutical Sciences , Sun Yat-Sen University , 132 East Circle at University City , Guangzhou 510006 , China.

出版信息

J Chem Inf Model. 2019 Jul 22;59(7):3277-3290. doi: 10.1021/acs.jcim.9b00292. Epub 2019 Jun 26.

Abstract

Liver X receptors (LXRα/β), sensors of cholesterol, are involved in regulation of lipid metabolism and are promising drug targets against many diseases, including atherosclerosis, metabolic syndromes, and cancers. Activation of LXRα can cause adverse effects, and a current focus is a search for LXRβ-selective agonists. An understanding of the ligand-selective mechanisms is critical in the design and identification of LXRβ-selective ligands because the α- and β-isoforms LXRα-Val263 and LXRβ-Ile277 have only minor structural differences in the ligand binding domain (LBD). In this work, and studies were performed. For the first time, we report that the ligand LXRβ-selectivity relies on structural differences between LXRα-Val263 and LXRβ-Ile277 and also on conformational changes at Leu274 and Ala275. These residues are the same in both α- and β-isoforms, but their conformational changes when interacting with selective ligands are different. Mutation studies indicate that replacing both Val263 and Ile277 with alanine residues does not completely nullify the β-selectivity. High β-binding selectivity can be related to the synergistic effects of other residues that interact with the ligand in the LBD, although these residues are identical in both LXRα and LXRβ. This work offers a path to the design and optimization of selective LXRβ agonists.

摘要

肝 X 受体 (LXRα/β) 作为胆固醇的感应器,参与脂质代谢的调控,是治疗动脉粥样硬化、代谢综合征和癌症等多种疾病的有希望的药物靶点。LXRα 的激活可能会产生不良反应,目前的研究重点是寻找 LXRβ 选择性激动剂。了解配体选择性机制对于设计和鉴定 LXRβ 选择性配体至关重要,因为 LXRα-Val263 和 LXRβ-Ile277 两种异构体在配体结合域 (LBD) 仅有微小的结构差异。在这项工作中,进行了 和 研究。我们首次报道,配体的 LXRβ 选择性依赖于 LXRα-Val263 和 LXRβ-Ile277 之间的结构差异,以及 Leu274 和 Ala275 处的构象变化。这些残基在两种异构体中是相同的,但它们与选择性配体相互作用时的构象变化不同。突变研究表明,用丙氨酸残基替换 Val263 和 Ile277 并不能完全消除β选择性。高β结合选择性可能与与 LBD 中的配体相互作用的其他残基的协同效应有关,尽管这些残基在 LXRα 和 LXRβ 中是相同的。这项工作为设计和优化选择性 LXRβ 激动剂提供了一条途径。

相似文献

1
Structurally Selective Mechanism of Liver X Receptor Ligand: and Studies.肝 X 受体配体的结构选择性机制: 和 研究。
J Chem Inf Model. 2019 Jul 22;59(7):3277-3290. doi: 10.1021/acs.jcim.9b00292. Epub 2019 Jun 26.
8
Ligands of Therapeutic Utility for the Liver X Receptors.肝脏X受体的治疗用配体
Molecules. 2017 Jan 5;22(1):88. doi: 10.3390/molecules22010088.
10
Discovery of new LXRβ agonists as glioblastoma inhibitors.发现新的 LXRβ 激动剂作为脑胶质瘤抑制剂。
Eur J Med Chem. 2020 May 15;194:112240. doi: 10.1016/j.ejmech.2020.112240. Epub 2020 Mar 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验